Scaling‐Up Research in Childhood Cancer in Low‐ and Middle‐Income Countries
- 5 April 2026
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (6) , e70254
Abstract
Childhood cancer outcomes in low‐ and middle‐income countries (LMICs), where over 80% of the world's children reside, remain drastically lower than in high‐income countries (HICs). This vast disparity stems from pervasive challenges, including limited healthcare access, inadequate resources, delayed diagnosis, and differences in disease biology influenced by varied genetic ancestries. The direct translation of intensive HIC protocols often results in elevated treatment‐related mortality (TRM) in resource‐constrained settings, highlighting the critical need for locally validated regimens. Current barriers to establishing robust research capacity include minimal research training, overwhelmed specialists, excessive and misaligned ethical/regulatory oversight—even for low‐risk studies—and pharmaceutical industry strategies that favor trials in HICs. To bridge this survival gap, a paradigm shift is required, moving from protocol translation to context‐specific clinical research. This strategy must prioritize Implementation and Comparative Effectiveness studies to validate adapted treatments. Key initiatives must include local genomic characterization for equitable risk allocation and an innovative “repurposing” of novel agents by adjusting dosages and schedules to enhance feasibility and reduce toxicity within local supportive care capacity. Strengthening international cooperative research groups and fostering a multi‐stakeholder dialogue among regulators, industry, and civil society are essential to expedite the generation of robust, locally relevant evidence that can inform public health policy and ensure every child has access to the best chance of cure at their local site.Keywords
This publication has 34 references indexed in Scilit:
- A soaring price, a silent fight: Thioguanine portends new access barriers to life‐saving treatments for children with cancerPediatric Blood & Cancer, 2024
- International Society of Paediatric Oncology (SIOP) Global Mapping Program: Analysis of healthcare centers in countries of the Latin American Society of Pediatric Oncology (SLAOP)Pediatric Blood & Cancer, 2024
- The grander challenge of pediatric oncology: Disparities in access to carePediatric Blood & Cancer, 2021
- Pediatric cancer care in Africa: SIOP Global Mapping Program report on economic and population indicatorsPediatric Blood & Cancer, 2021
- Neuroblastoma: The basis for cure in limited‐resource settingsPediatric Blood & Cancer, 2021
- Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in IndiaPediatric Blood & Cancer, 2020
- What 20 years of research has taught us about the TP53 p.R337H mutationCancer, 2020
- Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort studyCancer, 2020
- A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory MalignanciesPediatric Blood & Cancer, 2015
- Protocol‐based treatment for children with cancer in low income countries in Latin America: A report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)—Part IIPediatric Blood & Cancer, 2007